Search Results

outcomes and streamlining health care delivery via several mechanisms: the creation of accountable care organizations (ACOs), a shift away from fee-for-service payment structures to payment bundling, and increased funding for comparative-effectiveness

comparative effectiveness research (CER) project: overview and methodology . J Registry Manag 2014 ; 41 : 103 – 112 . 25419602 16. Howlader N , Altekruse SF , Li CI , . US incidence of breast cancer subtypes defined by joint hormone receptor and

medicine in breast cancer . J Oncol Pract 2012 ; 8 : e24 – 31 . 47. Trosman JR Weldon CB Schink JC . What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast

be expanded throughout Medicare, Medicaid, and CHIP. This program is effective January 1, 2011. Comparative Effectiveness Research Although payors currently use coverage policies and reimbursement models to control costs and use, comparative

resources. 29 Longitudinal, comparative effectiveness research on the benefits, harms, and health care use after the receipt of DTC or incidental results from NGS is needed, including comparative observational and randomized trials; assessment of patient

data set, such as a national oncology database, and conduct comparative effectiveness research to evaluate the utilization trends among available treatment modalities for localized prostate cancer. The authors have disclosed that they have no

comparative effectiveness research . Qual Life Res 2013 ; 22 : 1889 – 1905 . 30. Group AS . Health-related quality of life and psychological distress among cancer survivors in Southeast Asia: results from a longitudinal study in eight low- and

Medicine and Comparative Effectiveness Research Trastuzumab is an FDA-approved drug for women with known Her2/neu -positive advanced and earlystage breast cancer. In the United States, up to 20% of patients receiving trastuzumab were not tested for and

technologies that allow patients to access potentially beneficial care that without coverage would not be an option. 29 This may also allow for comparative effectiveness research that payors have not typically engaged in, as more data are gathered and

overview of the use and adoption of brain SRS in the modern era of RT for brain metastases, serves as a foundation for further research into drivers of uptake and disparities, and highlights the need for prospective comparative effectiveness research in